-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Long-Term Effects Monitoring for Survivors of Pediatric Hematologic Malignancies

Program: Education Program
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), epidemiology, Clinical Research, health outcomes research, Adverse Events, survivorship
Monday, December 12, 2022: 4:30 PM-5:45 PM
288-290 (Ernest N. Morial Convention Center)

Description:
Survivors of pediatric hematologic malignancies are at increased risk of long-term medical and psychosocial late effects as a consequence of their treatment, and in some instances, also secondary to underlying genetic predisposition. This educational session will review the evidence for three particularly significant toxicity categories: cardiovascular, neurocognitive, and secondary malignant neoplasms. The session will also review current screening and intervention strategies that may mitigate the development of these late effects. Finally, presenters will also highlight gaps and areas of future research.   

Dr. Eric Chow will provide background on the epidemiology of long-term treatment associated cardiovascular toxicity. He will then review current prevention and screening strategies, and touch on key management considerations.

Dr. Kevin Krull will outline the risk factors that are associated with neurocognitive deficits after therapy. In this session Dr. Krull also will review potential screening options, along with primary and secondary prevention options under current study.

Dr. Smita Bhatia will review the growing data informing genetic risk factors for secondary malignant neoplasms following cancer therapies, and the potential pathophysiologic pathways they reveal. Finally, she will discuss how these data can be incorporated into future screening and prediction algorithms.

Chair:
Eric J Chow, MD, MPH, ARRAY(0xf0a7cac)
Disclosures:
Chow: Abbott Laboratories: Research Funding.
Survivors of pediatric hematologic malignancies are at increased risk of long-term medical and psychosocial late effects as a consequence of their treatment, and in some instances, also secondary to underlying genetic predisposition. This educational session will review the evidence for three particularly significant toxicity categories: cardiovascular, neurocognitive, and secondary malignant neoplasms. The session will also review current screening and intervention strategies that may mitigate the development of these late effects. Finally, presenters will also highlight gaps and areas of future research.   

Dr. Eric Chow will provide background on the epidemiology of long-term treatment associated cardiovascular toxicity. He will then review current prevention and screening strategies, and touch on key management considerations.

Dr. Kevin Krull will outline the risk factors that are associated with neurocognitive deficits after therapy. In this session Dr. Krull also will review potential screening options, along with primary and secondary prevention options under current study.

Dr. Smita Bhatia will review the growing data informing genetic risk factors for secondary malignant neoplasms following cancer therapies, and the potential pathophysiologic pathways they reveal. Finally, she will discuss how these data can be incorporated into future screening and prediction algorithms.

Kevin R. Krull, PhD

St. Jude's, MEMPHIS, TN

Smita Bhatia, MD, MPH

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL

See more of: Education Program